User profiles for Ugur Sahin
 | Ugur SahinProfessor of Immunology Verified email at uni-mainz.de Cited by 68254 |
[HTML][HTML] mRNA-based therapeutics—developing a new class of drugs
In vitro transcribed (IVT) mRNA has recently come into focus as a potential new drug class to
deliver genetic information. Such synthetic mRNA can be engineered to transiently express …
deliver genetic information. Such synthetic mRNA can be engineered to transiently express …
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
U Sahin, E Derhovanessian, M Miller, BP Kloke… - Nature, 2017 - nature.com
T cells directed against mutant neo-epitopes drive cancer immunity. However, spontaneous
immune recognition of mutations is inefficient. We recently introduced the concept of …
immune recognition of mutations is inefficient. We recently introduced the concept of …
[HTML][HTML] Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
…, S Mather, PR Dormitzer, U Şahin… - New England journal …, 2020 - Mass Medical Soc
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and
the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in …
the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in …
[HTML][HTML] Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
…, AR Falsey, PR Dormitzer, WC Gruber, U Şahin… - Nature, 2020 - nature.com
In March 2020, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19),
which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-…
which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-…
Personalized vaccines for cancer immunotherapy
Cancer is characterized by an accumulation of genetic alterations. Somatic mutations can
generate cancer-specific neoepitopes that are recognized by autologous T cells as foreign …
generate cancer-specific neoepitopes that are recognized by autologous T cells as foreign …
[HTML][HTML] SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3
Immune Response to a Third Dose of BNT162b2 A third dose of the BNT162b2 vaccine was
administered to 23 volunteers 8 to 9 months after the second dose, and the immune …
administered to 23 volunteers 8 to 9 months after the second dose, and the immune …
[HTML][HTML] Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months
…, S Mather, PR Dormitzer, U Şahin… - … England Journal of …, 2021 - Mass Medical Soc
Background BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine
encoding a prefusion-stabilized, membrane-anchored severe acute respiratory syndrome …
encoding a prefusion-stabilized, membrane-anchored severe acute respiratory syndrome …
[HTML][HTML] Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates
…, PR Dormitzer, KU Jansen, U Şahin… - … England Journal of …, 2020 - Mass Medical Soc
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections
and the resulting disease, coronavirus disease 2019 (Covid-19), have spread to millions of …
and the resulting disease, coronavirus disease 2019 (Covid-19), have spread to millions of …
[HTML][HTML] CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial
The oncofetal antigen Claudin 6 (CLDN6) is highly and specifically expressed in many solid
tumors, and could be a promising treatment target. We report dose escalation results from …
tumors, and could be a promising treatment target. We report dose escalation results from …
[HTML][HTML] Bivalent Omicron BA. 1–Adapted BNT162b2 booster in adults older than 55 years
Background The emergence of immune-escape variants of severe acute respiratory
syndrome coronavirus 2 warrants the use of sequence-adapted vaccines to provide protection …
syndrome coronavirus 2 warrants the use of sequence-adapted vaccines to provide protection …